Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Dipharma
Dipharma
Activities:
Ingredients
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Overcoming CMC challenges in cell and gene therapy: part I
Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC...
Resolving capping issues in tablet manufacturing
Natoli explores the various causes of capping and the methods to prevent it
Effective ways to optimise heat exchangers
Heat exchangers are used within a wide range of process industries as a way to transfer heat between two fluid streams across a medium in an energy conservative way
Transforming healthcare with patient centricity
In this opinion article, John Kytariolos, Head of Clinical and Scientific Affairs at Adragos Pharma, discusses patient-centric dosage forms, their properties and the impact...
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Manufacturing
Dipharma expands CDMO offering with new QC lab in the US
New lab has enabled Italy-based Dipharma to now offer full services from discovery to marketed drugs
Manufacturing
Dipharma Francis Srl sell Amino Chemicals to ABA Chemicals
Dipharma Francis Srl, a European manufacturer of Active Pharmaceutical Ingredients, completed the sale of its subsidiary Amino Chemicals, based in Malta, to ABA Chemicals Corporation, China
Research & Development
New room-temperature stable Carglunic acid tablets
Carglumic acid is a therapeutic tool in the management of inborn metabolic disorders affecting the urea cycle
Pharmaceutical
Disanit authorised for marketing in Europe
Dipharma's Disanit (Nitisinone capsules 2, 5 and 10mg) is now under marketing authorisation (MA) evaluation in the EU.
Distribution
Dipharma and Alvogen launch Diterin in South Korea
First drug commercially available for the treatment of hyperphenylalaninemia due to phenylketonuria
Subscribe now